Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Biology — the science of life, living things and the processes that keep us all running — links up in essential ways with ...

Gennova Biopharmaceuticals Ltd. on Tuesday announced that it is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI), a subsidiary of Emcure Pharmaceuticals Ltd. for the ...